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Methods: Two double-blind, 12-month, parallel-group, non-inferiority trials
comparing as-needed use of formoterol (Oxiss) 4.5 mg and terbutaline (Bricanyls)
0.5mg via dry-powder inhaler (Turbuhalers), one in 675 patients with intermittent
and one in 455 patients with mild persistent asthma, overall 6–87 years of age. Peak
expiratory flow (PEF), symptoms, rescue medication use, exacerbations, airway
responsiveness (metacholine challenge; subgroup of 127 patients), systemic effects
(high single-dose test; subgroup of 87 patients), and safety (adverse events) were
assessed.
Results: Formoterol 4.5 mg was as effective as terbutaline 0.5mg with regard to
morning PEF (non-inferiority; lower 95% confidence interval limit above 10 L/min).
Metacholine sensitivity, exacerbation rates or use of rescue medication did not differ
between treatments. Formoterol 54 mg was shown to give less systemic effects than
terbutaline 6mg. Both treatments were safe and well tolerated.
Conclusions: Formoterol 4.5 mg used as needed was at least as effective and safe
as terbutaline 0.5mg used as needed in intermittent and mild persistent asthma, and
was associated with less systemic effects when administered as high single doses.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Asthma is a variable disease with variations in the
magnitude of the chronic airway inflammation over
time.1 Bronchodilators are used to alleviate pa-
tients’ symptoms caused by this variability, and
traditionally short-acting b2-agonists have been
used as needed for this purpose. In addition to its
rapid onset of bronchodilatory effect, inhaled
formoterol fumarate dihydrate (hereafter formo-
terol) also has a long duration of action (up to
12 h).2 Formoterol used as needed has been shown
to have a beneficial impact on asthma control
compared with established treatment with short-
acting b2-agonists in patients with moderate to
severe asthma.3 However, by virtue of its long
duration of action, concerns have been raised that
formoterol could mask a worsening of the airway
inflammation, leading to a delay in introducing or
properly adjusting concomitant anti-inflammatory
therapy.4,5 All patients with persistent asthma
should be continuously treated with an inhaled
corticosteroid (ICS) or other anti-inflammatory
treatment and not solely a b2-agonist, neither long-
or short-acting alternatives.1 However, the use of
formoterol without concomitant anti-inflammatory
treatment in patients with intermittent asthma
should not be precluded a priori.
The primary objectives were to study the
effectiveness and safety of as-needed treatment
of formoterol compared with the short-acting
alternative terbutaline sulphate (hereafter terbu-
taline), both given via a dry-powder inhaler
(Turbuhaler) to patients with intermittent or mild
persistent asthma, classified according to GINA
guidelines.1 A non-inferiority study design was
used. Various measures, including bronchial hyper-
sensitivity to methacholine in a subgroup of
patients, were used to investigate whether the
as-needed treatments affected asthma control
differently. High-dose tolerability tests with for-
moterol and terbutaline were performed in another
subgroup of patients.Methods
This paper is based on two separate 12-month
clinical trials with identical protocols; one trial in
patients with intermittent asthma and one trial in
patients with mild persistent asthma. Both trials
had a randomised, double-blind, multi-centre,
parallel-group design and were stratified for age
in three groups (children p11 years, adolescents
12–17 years, and adults X18 years old). The trialswere performed in accordance with the declaration
of Helsinki and approved by the local ethics
committees at each site.Patients
PatientsX6 years with asthma diagnosed according
to ATS criteria and a baseline forced expiratory
volume during the first second (FEV1) X80% of
predicted normal were eligible. patients who had
used long-acting b2-agonists within 3 months prior
to enrolment were excluded. A respiratory infec-
tion affecting the asthma within 4 weeks prior to
enrolment, severe cardiovascular disorders, such as
ischemic heart disease, tachyarrhythmias or severe
heart failure, or a smoking history of X10 pack-
years were other exclusion criteria. Women who
were pregnant, breast-feeding or not using an
acceptable method of contraception were also
excluded. Intermittent asthmatics should not have
used ICS or other anti-inflammatory treatment
within 3 months prior to enrolment, and have a
need for terbutaline as reliever between two and
six occasions (one occasion could include more than
one dose) during the last 14 days of the run-in
period. Mild persistent asthmatics were to be on
regular treatment with a stable dose of an ICS
(200–500 mg/day), nedocromil or cromoglycate,
and have a need for terbutaline as reliever X3
times/week butp4 times/day during the run-in
period. Written informed consent was obtained
before conducting any study-related procedures.Study design
Eligible patients entered a 3-week run-in period
during which they received terbutaline (Bricanyls)
0.5mg as needed via the dry-powder inhaler
Turbuhalers in a single-blind manner. At visit 2,
patients were randomised to either proceed with
the same treatment or be shifted to formoterol
(Oxiss) 4.5 mg as needed via Turbuhaler, double-
blind during 12 months. To show the effect of
formoterol in a placebo-controlled design was not
considered feasible for ethical reasons. Patients
attended the clinic at nine occasions, at enrol-
ment, at randomisation, and after 1, 2, 4, 6, 8, 10
and 12 months treatment. Between visits patients
were contacted by telephone to check adverse
events (AEs) and compliance with study proce-
dures.
Severe asthma exacerbations were defined as the
need for an oral steroid course or hospitalisation
due to asthma. Patients were treated with
prednisolone or prednisone 1–2mg/kg or 30mg/day,
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at an equivalent dose, for 10 days. A longer
treatment period or a second severe asthma
exacerbation led to withdrawal from the study.
Two subgroups were selected to attend the clinic
for more visits. One group tested the safety of a
high single dose of the study medication at one
occasion near the end of treatment. Patients X12
years at the day of the test and with a special
written informed consent were given 12 inhalations
of the study medication, i.e. 54 mg of formoterol or
6mg of terbutaline. Another group of patientsX12
years attended the clinic at two occasions, once
before randomisation and once near the end of
treatment, for methacholine challenge tests. Pa-
tients were only to participate in one of the
subgroups.Assessments
The patients (parents/legal guardian) filled in a
diary throughout the study, including the 3-week
run-in period. Recordings were made of peak
expiratory flow (PEF) before intake of any medica-
tion in the morning directly after wakening and at
bed time, of the use of study medication during
day-time and night-time and of day-time and night-
time asthma symptoms (scored 0–4 with 0 indicat-
ing no symptoms and 4 severe symptoms).
FEV1 was measured at all clinic visits, at visits
2–9 both before and 30min after one inhalation of
the study medication. The clinics were allowed to
use their own spirometers, provided that they met
the ATS criteria. The spirometry tests should be
performed at the same time of the day for all visits
and within 71 h from visit 1. Predicted values for
FEV1 was calculated according to Quanjer et al. for
adults6 and for adolescents and children.7
Provocation dose of methacholine giving a 20%
decrease in FEV1 (PD20) methacholine was deter-
mined twice in subsets of patients in both trials,
before randomisation and after 10–12 months of
study treatment. Children p11 years of age and
patients who had any viral infection or asthma
exacerbation within 4 weeks were not to perform
the tests. The methacholine challenge was per-
formed with a MEFAR MB 3 dosimetric jet (local
deviations occurred), the output value of which
was calibrated before each test.8 Baseline FEV1 was
measured after a 30-min rest, then a physiological
saline solution was inhaled and FEV1 reassessed.
The challenge was stopped if the fall in FEV1 from
pre- to post-saline was 410%. Then methacholine
was given in doubling doses up to a maximum
cumulative dose of 3mg, with FEV1 measured 2minafter each methacholine step. The challenge was
stopped when a 20% fall in FEV1 relative to the
post-saline value had been reached or the max-
imum dose of methacholine had been given. PD20
was determined from linear interpolation in the
cumulative dose (logged) versus effect (percentage
change from post-saline) graph. After the provoca-
tion patients were given one dose of the study
medication, and FEV1 was monitored until it had
returned to 90% of the baseline value.
High single-dose tests were performed after
10–12 months of study treatment in other subsets
of patients in both trials. Patients arrived at the
clinic fasting. Administration of 12 doses in a row of
the study medication was performed at zero time.
The first 4-h measurements were made before
intake of any food or beverage, with the exception
of water. Serum potassium, blood glucose, blood
pressure and a 12-lead resting electrocardiogram
(ECG) was monitored pre-dose and at 30min, 1, 4
and 8 h following drug administration. Measure-
ments were summarised as an 8-h average value
and as the minimum (serum potassium, diastolic
blood pressure) or maximum value (other variables)
measured. Serum potassium analyses were per-
formed at the clinical laboratory at the hospital
according to established routines.
AEs were collected by means of standardised
questions at arrival at the clinic at visits 2–9, at all
telephone contacts, at the high single-dose visit,
and at the methacholine challenge visits.
Routine laboratory tests (haematology, clinical
chemistry, urinalysis), pulse, blood pressure and
ECG were recorded at study entry and at study
completion.Statistics
Data from the two trials were analysed separately,
with the exception of subgroup data on high-dose
tolerability and methacholine challenges, which
were pooled. For diary card variables, the change
from the mean over the run-in period to the mean
over the 1-year treatment period was compared
between treatments using an analysis of variance
(ANOVA) model with treatment and country as
factors and the run-in mean as covariate. From the
high single-dose test, 8-h averages and minimum or
maximum effects were compared between treat-
ments using an ANOVA model with treatment and
country as factors and the pre-dose value of the
study day as covariate. Pre- and post-dose FEV1 and
PD20 methacholine were compared using similar
multiplicative ANOVA models, i.e. data were logged
prior to analysis. Time to first severe asthma
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Figure 1 Number of patients enrolled, randomised and
completed by treatment group.
A. Chuchalin et al.464exacerbation was compared between treatments
using a Cox proportional hazards model. With-
drawal rates were compared using the log-rank
test. AEs were analysed by means of descriptive
statistics and qualitative analysis. Differences in
proportion of patients with AEs were compared
using the w2-test.
For non-inferiority testing (morning PEF) the per-
protocol population was used. The per-protocol
population excluded all data from non-eligible
patients, data collected during use of unallowed
medications, and data collected after a second
asthma exacerbation. Two-sided 95% confidence
intervals were computed for the difference be-
tween formoterol and terbutaline. Non-inferiority
was declared if the lower limit of the confidence
interval exceeded 10 L/min. For superiority test-
ing the full analysis set was used, including all
randomised patients with intermittent or mild
persistent asthma according to protocol and with
data collected after randomisation. The safety data
set included all randomised patients with data
collected after randomisation. All tests were two-
sided at a 5% significance level (where applicable).
It was estimated that with 500 randomised patients
per trial (250 in each treatment group), there
was an 80% chance of declaring non-inferiority
provided that there were no actual differences
between the treatments and the standard
deviation was 40 L/min.Results
Patient flow and demographics
The number of patients enrolled, randomised and
completed by treatment group and study are shown
in Fig. 1. In the trial with intermittent asthmatics,
51 patients (formoterol 23, terbutaline 28) were
withdrawn (not significant, P ¼ 0:60). One patient
(terbutaline) had no data collected and two
patients (both terbutaline) had only safety data
collected. Twenty-five patients (formoterol 11,
terbutaline 14) had an average use of terbutaline
during run-in exceeding the upper protocol defined
limit (six occasions during last 14 days) and were
excluded from the full analysis set. The safety data
set consisted of 674 patients (formoterol 333,
terbutaline 341), the full analysis data set of 647
patients (formoterol 322, terbutaline 324) and the
per-protocol analysis set of 629 patients (formoter-
ol 316, terbutaline 313). In the trial with mild
persistent asthmatics, 31 patients (formoterol 11,
terbutaline 20) were withdrawn (not significant,P ¼ 0:09). Both the safety and the full analysis set
consisted of all 455 randomised patients, the per-
protocol analysis set of 374 patients (formoterol
191, terbutaline 183).
Demographical data was well balanced between
the treatment groups in both trials (Table 1). Of the
mild persistent asthmatics, 430 (95%) patients were
on concomitant treatment with ICS, and 39 (9%)
patients were on other anti-inflammatory treat-
ment, nedocromil or cromoglycate.Efficacy
Formoterol was shown to be non-inferior to
terbutaline in both asthma populations studied
based on the mean change from run-in to the 1-
year treatment period average in morning PEF
(non-inferiority limit 10 L/min). Estimated mean
differences (formoterol versus terbutaline; per-
protocol population) were 2.9 L/min for intermit-
tent asthmatics 95% confidence interval, CI (–3.2,
9.0) and 5.5 L/min for mild persistent asthmatics
95% CI (3.7, 14.7). The increase in morning PEF
over the 1-year treatment period was in parallel for
formoterol and terbutaline (Fig. 2).
No statistically significant differences (full ana-
lysis set) were found between groups on morning or
evening PEF, night-time or day-time asthma symp-
toms, use of study medication or post-dose FEV1 in
neither asthma population (Table 2). On pre-dose
FEV1 there was a statistically significant difference
in favour of formoterol in the mild persistent
patients but not in the intermittent patients.
The use of study medication were unchanged
(intermittent) or decreased slightly (mild persis-
tent) during the treatment period (Fig. 2). An
intake of more than 4 doses/day were reported on
0.14% (formoterol) and 0.22% (terbutaline) of the
study days for intermittent asthmatics and on 1.24%
(formoterol) and 1.60% (terbutaline) of the study
days in the mild persistent asthmatics.
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Table 1 Demography and baseline characteristics at study entry (all randomised patients).
Variable Intermittent asthma Mild persistent asthma
Formoterol Terbutaline Formoterol Terbutaline
N 333 342 228 227
Gender: male n (%) 194 (58) 208 (61) 113 (50) 119 (52)
Age (years): mean (range) 23 (6–73) 24 (6–87) 25 (6–75) 25 (6–67)
Children: n (%) 75 (23) 71 (21) 57 (25) 61 (27)
Adolescents: n (%) 98 (29) 105 (31) 45 (20) 38 (17)
Adults: n (%) 160 (48) 166 (49) 126 (55) 128 (56)
FEV1 (L): mean (range) 3.11 (0.98–5.56) 3.15 (1.14–6.80) 2.91 (1.12–5.38) 2.92 (0.96–5.77)
FEV1 (% predicted
normal): mean (range)
101 (80–170) 100 (76–169) 98 (80–174) 97 (79–166)
Terbutaline rescue
medication during run-in,
No. of inhalations/day:
mean (range)
0.36 (0.09–3.21*) 0.41 (0.05–6.00*) 1.3 (0.2–4.1) 1.4 (0.4–4.4)
Symptom-free days (%):
mean (range)
62 (0–100) 62 (0–100) 34 (0–100) 35 (0–100)
Inhaled corticosteroid
dose (mg): mean (range)
Not applicable Not applicable 376 (200–900) 388 (200–800)
*Includes 25 non-eligible patients.
Figure 2 Daily means of the change from run-in to treatment in morning PEF (per-protocol analysis set) and daily means
of the change from run-in to treatment in use of study medication (full analysis set).
Formoterol used as needed 465
ARTICLE IN PRESS
Table 2 Efficacy results (full analysis set).
Variable Intermittent asthma Mild persistent asthma
Difference 95% CI P-value Difference 95% CI P-value
Morning PEF (L/min) 3.0 (3.1, 9.1) 0.34 6.3 (1.9, 14.5) 0.13
Evening PEF (L/min) 2.0 (4.1, 8.1) 0.52 4.3 (3.9, 12.6) 0.30
Night-time symptoms (score 0–4) 0.01 (0.02, 0.03) 0.65 0.05 (0.11, 0.00) 0.06
Day-time symptoms (score 0–4) 0.01 (0.04, 0.02) 0.54 0.03 (0.09, 0.03) 0.29
Use of study medication (doses/day) 0.01 (0.03, 0.06) 0.58 0.13 (0.29, 0.02) 0.09
Pre-dose FEV1 (ratio in %) 98.9 (97.4, 100.4) 0.14 101.9 (100.1, 103.7) 0.04
Post-dose FEV1 (ratio in %) 99.1 (97.7, 100.6) 0.24 100.4 (98.9, 101.9) 0.61
Mean differences between formoterol and terbutaline.
A. Chuchalin et al.466Severe asthma exacerbations
Severe asthma exacerbations occurred with a low
but similar frequency in both treatment groups. In
intermittent asthmatics, 32 patients (formoterol
18, terbutaline 14) experienced 33 severe asthma
exacerbations (formoterol 18, terbutaline 15). Of
these 3 exacerbations (formoterol 1, terbutaline 2)
were due to hospitalisations. One exacerbation
(terbutaline) resulted in withdrawal due to AE. In
mild persistent asthmatics, 42 patients (formoterol
17, terbutaline 25) experienced 46 severe asthma
exacerbations (formoterol 19, terbutaline 27). Of
these 6 exacerbations (formoterol 2, terbutaline 4)
were due to hospitalisations. Three exacerbations
(formoterol 1, terbutaline 2) resulted in withdrawal
due to AEs. There was no statistically significant
difference in time to first exacerbation in inter-
mittent (hazard ratio formoterol versus terbutaline
1.3, 95% CI (0.6, 2.6), P ¼ 0:46) or mild persistent
asthmatics (hazard ratio 0.6, 95% CI (0.3, 1.1),
P ¼ 0:12).Adverse events and routine laboratory tests
In the intermittent asthmatics 61% (formoterol) and
59% (terbutaline), and in the mild persistent
asthmatics 58% (formoterol) and 68% (terbutaline)
of the patients experienced at least one AE during
the study, excluding AEs starting during the high
single-dose test day (Table 5). The most frequently
reported were all related to infections in the
respiratory system, probably reflecting the under-
lying disease, i.e. respiratory infections (total for
both studies: formoterol 152, terbutaline 151),
rhinitis (formoterol 78, terbutaline 79), pharyngitis
(formoterol 46, terbutaline 59), bronchitis (formo-terol 45, terbutaline 45) and viral infections
(formoterol 49, terbutaline 37).
There were no differences in the total number of
serious adverse events (SAEs) or in the number of
asthma-related SAEs or in discontinuation due to
adverse events (DAEs) in either study (Table 5). No
deaths occurred in the studies. None of the SAEs
were considered to be caused by the study drugs, as
judged by the investigators.
Routine laboratory measurements, pulse, blood
pressure and ECG taken at study entry and at study
completion revealed no safety issues in either
study.Methacholine challenge
In a subset of patients, methacholine challenges
were performed once during run-in and once near
the end of the 1-year treatment period. In total,
127 patients (formoterol 67, terbutaline 60) per-
formed both visits. The majority of the patients
were intermittent asthmatics (Table 3). For 3
patients (formoterol 2, terbutaline 1) no PD20 could
be determined from one of the test days (lack of
data) and they have been excluded from analysis.
The median time since last study drug intake at
start of challenge was 69 h. The mean (cumulative)
PD20 at baseline was 0.28mg in the formoterol
group and 0.25mg in the terbutaline group. The
mean change in PD20 during the study was small in
both groups. There was no difference between
formoterol and terbutaline in PD20 at near end of
treatment (PD20 ratio 87.1%, 95% CI (53, 142),
P ¼ 0:58). During the study, PD20 decreased with
one dose step or more in 26 patients (formoterol
15, terbutaline 11) and increased with one dose
step or more in 34 patients (formoterol 21,
terbutaline 13).
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Table 3 Demography and baseline characteristics for the subgroups (at study entry).
Variable Metacholine challenge Tolerability test
Formoterol Terbutaline Formoterol Terbutaline
N 67 60 43 44
Gender: male, n (%) 42 (63) 44 (73) 26 (61) 26 (59)
Age (years): mean (range) 24 (12–63) 23 (12–58) 24 (11*–61) 21 (11*–43)
Adolescents: n (%) 98 (29) 105 (31) 18 (42) 23 (52)
Intermittent asthmatics: n (%) 59 (88) 51 (85) 39 (91) 39 (89)
FEV1 (% predicted normal): mean (range) 100 (80–155) 98 (80–132) 103 (81–165) 102 (82–155)
No. of terb. inh: mean (range) 0.39 (0.09–2.01) 0.43 (0.11–1.86) 0.53 (0.09–2.73) 0.56 (0.18–3.90)
Symptom-free days (%): mean (range) 60 (0–100) 60 (0–95) 58 (0–91) 58 (0–86)
Inhaled corticosteroid: n (%) 8 (12) 9 (15) 4 (9) 5 (11)
Dose (mg): mean (range) 519 (400–900) 428 (250–700) 313 (200–400) 320 (200–400)
*All patients were 12 years old at the actual study day.
Formoterol used as needed 467High dose tolerability and safety
In a subset of 87 patients (formoterol 43,
terbutaline 44), a high single-dose test with
formoterol 54 mg or terbutaline 6mg was
performed at the near end of the treatment period.
The majority of patients were intermittent
asthmatics (Table 3). Mean value curves for serum
potassium, blood glucose, heart rate and heart
rate corrected QT interval (QTc) are given in
Fig. 3. There were statistically significantly
less systemic effects in the formoterol group as
measured by 8-h average serum potassium and
heart rate (Table 4). Also, formoterol gave
statistically significantly less systemic effects as
measured by minimum serum potassium, and
maximum systolic blood pressure, heart rate and
QTc (Table 4).
In patients with normal serum potassium values
at baseline, 6 patients (formoterol 2, terbutaline 4)
had post-dose values below 3.0mmol/L and 23
patients (formoterol 6, terbutaline 17) showed
decreases from pre- to post-dose of 1.0mmol/L or
more. Similarly on QTc, 13 patients (formoterol 6,
terbutaline 7) had post-dose values above 460ms
(adolescents 445ms) and 18 patients (formoterol 6,
terbutaline 12) showed increases from pre- to post-
dose of 50ms or more.
Fifteen (35%) patients in the formoterol group
experienced 30 AEs and 28 (64%) patients in the
terbutaline group experienced 59 AEs during the
high-dose day. This difference in patients with AEs
was statistically significant (P ¼ 0:007). The most
frequently reported AEs by preferred term were
tremor (formoterol 8 patients, terbutaline 22),
tachycardia (formoterol 8, terbutaline 10) and
palpitation (formoterol 1, terbutaline 7), all well-known class effects of b2-agonists. No SAEs or DAEs
were reported during the single high-dose day
(Table 5).Discussion
In summary, these two non-inferiority 12-months
clinical trials showed that formoterol was at least
as effective as terbutaline when used as needed in
patients with intermittent or mild persistent
asthma. Methacholine sensitivity did not change
during the course of the study, the exacerbation
rate was the same, and the need for formoterol did
not increase compared with terbutaline in the
patients with intermittent asthma, i.e. not on
concomitant treatment with ICS. This suggests that
formoterol did not aggravate masking of airway
inflammation compared with terbutaline. In a
subset of patients, a high single dose of formoterol
(54 mg) was shown to give less systemic effects than
a corresponding dose of terbutaline (6mg), as
measured by serum potassium, systolic blood
pressure, heart rate and QTc, and was associated
with less AEs.
A better efficacy profile of formoterol as needed
compared to terbutaline has previously been shown
in moderate to severe asthmatics.3 In that study,
the mean use of rescue medication during run-in
was 5.2 doses/day. In our milder patient cate-
gories, lung function would be close to normal, and
a low need for rescue medication could be
anticipated. With low-frequent need of rescue
medication, the longer duration of bronchodilating
effect for formoterol would be of less importance.
Thus, the efficacy gains with formoterol over
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Table 4 Analysis of tolerability following high single dose test in a subgroup of patients.
Variable Average effect (Eav) Peak effect (Emin
+ or Emax* )
Difference 95% CI P-value Difference 95% CI P-value
Serum potassium (mmol/L)+ 0.21 (0.02, 0.39) 0.03 0.30 (0.14, 0.47) o0.001
Blood glucose (mmol/L)* 0.32 (0.72, 0.08) 0.11 0.57 (1.21, 0.07) 0.08
Systolic blood pressure (mmHg)* 2.7 (6.4 0.9) 0.14 4.2 (8.3, 0.2) 0.04
Diastolic blood pressure (mmHg)+ 0.2 (2.9, 2.5) 0.87 0.4 (3.6, 2.8) 0.80
Heart rate (beats per minute)* 6.2 (10.4, 2.0) 0.004 9.0 (14.3, 3.7) 0.001
QTc (ms)* 6.0 (15.2, 3.2) 0.20 14.6 (27.2, 2.1) 0.02
Mean differences between formoterol and terbutaline.
Figure 3 Mean value curves of selected systemic effects from the high single-dose test with formoterol 54 mg or
terbutaline 6mg in a subset of patients.
A. Chuchalin et al.468terbutaline was expected to be small and this
motivated the choice of a non-inferiority design
over a traditional superiority study. The non-
inferiority limit, 10 L/min, was chosen based on
previously published equivalence trials with PEF
morning using limits of 715 L/min,9,10 and an
expectation that formoterol would come out
numerically better than terbutaline. A placebo-
controlled design was not considered feasible for
ethical reasons.Recently, studies have been published highlight-
ing the possible risks using long-acting b2-agonists
on a regular basis without concomitant adequate
anti-inflammatory therapy. The SMART study was a
28-week safety study with over 25,000 patients
comparing regular treatment with salmeterol (Ser-
eventTM) and placebo in patients with asthma. In
the patients not receiving ICS at baseline (53%),
there was a statistically significantly greater
number of asthma-related deaths in patients taking
ARTICLE IN PRESS
Table 5 Summary of adverse events.
Intermittent asthma Mild persistent asthma
Formoterol Terbutaline Formoterol Terbutaline
No. of adverse events 363 380 299 350
No. of patients with AE (%) 204 (61) 202 (59) 133 (58) 155 (68)
No. of SAEs 7 7 14 15
Asthma-related 1 2 4 5
No. of patients with SAE (%) 6 (2) 6 (2) 12 (5) 13 (6)
No. of DAEs 0 2 2 3
Asthma-related 0 1 1 2
Formoterol used as needed 469salmeterol compared to those taking placebo.11 No
such difference was seen in ICS treated patients.
Mann et al.12 reported the outcome of a 1-year
study in children and two 12-week studies in adults
and adolescents with formoterol (ForadilTM). More
patients receiving formoterol 24 mg bid experienced
serious asthma exacerbations than those receiving
placebo, salbutamol or formoterol 12 mg bid.
Information on the use of ICSs is not given in the
article, but it was not a requirement for entry.
However, this should not preclude the possibility
to use formoterol as needed in patients with mild
persistent asthma using concomitant anti-inflam-
matory treatment or with intermittent asthma,
properly treated with low-frequent use of a
bronchodilator alone. As-needed use of formoterol
in patients without concomitant ICS has previously
been studied in the RELIEF study,13 in a cohort of
2800 out of 18,000 randomised patients. The
efficacy profiles of formoterol and salbutamol were
similar, and no differences in the rate of severe
asthma exacerbations or asthma-related SAEs were
found. In our study, including intermittent asth-
matics with a need for rescue medication between
2 and 6 occasions during the last 14 days of the run-
in period, no safety issues with formoterol could be
identified. The use of study medication did not
increase during the study, and days with a usage of
more than 18 mg of formoterol were very rare. This
shows that formoterol as needed could be used as
an alternative to short-acting b2-agonists also in
patients without the need for concomitant anti-
inflammatory treatment. However, to minimise the
risk for an under-treatment with anti-inflammatory
medication, patients with a need for rescue
medication, either long- or short-acting alterna-
tives, of more than two occasions per week should
be on concomitant treatment with an ICS.
Formoterol and terbutaline are functional an-
tagonists; the bronchodilating effect is attained,irrespective of the cause, by stimulation of b2-
adrenoceptors in the airway smooth muscles. The
bronchodilating effect is maintained,14 whereas
tolerance develops not only to the bronchoprotec-
tive effect15–17 but also to systemically mediated
effects such as palpitations and tremor, during
regular treatment.18,19 A larger number of ‘‘spare
receptors’’ or a higher level of gene expression for
the b2-adrenoceptor within than outside the lungs
may explain why bronchodilatation is maintained
while extrapulmonary effects are not.20 The reason
why tolerance to the bronchoprotective effect
develops, implying the possibility of increased
airway reactivity, is unclear. Possibly, a larger
number of b2-adrenoreceptors must be mobilised
to maintain smooth muscle relaxation in the
presence of a bronchoconstrictive substance. The
outcome of the present investigation indicated that
as-needed treatment marginally affected bronchial
reactivity upon methacholine challenge, no matter
if formoterol or terbutaline was used as reliever.
Further investigations are required to explore if the
reversing potential of formoterol and terbutaline is
maintained, too, under such conditions.
The bronchodilating effect of formoterol 4.5 mg
has been found to well match the bronchodilating
effect of salbutamol via pressurised metered dose
inhaler 200 mg,21 and in addition formoterol indi-
cated to have a better balance between therapeu-
tic and systemic effects than salbutamol.22
Clinically, salbutamol 200 mg and terbutaline
0.5mg are considered equiefficacious, and this
was the rational for the dose choice in the current
trials. In the emergency room setting, no differ-
ence in bronchodilating potential was seen be-
tween formoterol 4.5 mg and terbutaline 0.5mg.23
The high single-dose tests in the present trials
indicated that formoterol consistently gave less
systemic effects than terbutaline when using the
same dose relation. This relation has also been
ARTICLE IN PRESS
A. Chuchalin et al.470reported from other studies, both in adults18 and in
children (AstraZeneca, data on file). Thus, formo-
terol seems to have a more favourable balance
between therapeutic and systemic magnitudes of
effects than terbutaline, when administered in high
doses using this dose relation.
In conclusion, these studies showed that, in
intermittent and mild persistent asthmatics, for-
moterol 4.5 mg used as needed is at least as
effective and safe as terbutaline 0.5mg used as
needed, and is associated with less systemic effects
when administered as high single doses.Acknowledgements
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